🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for BRCA1 Mutation

Study Evaluating DNA Double-strand Breaks (DSBs) REpair Factors (POLQ, Shieldin Complex and 53BP1) Expression as Biomarker of PARP Inhibitor Resistance in Patients With Deleterious Germline Mutation in BRCA 1/2 and HER2-negative, Metastatic or Locally Advanced Breast Cancer. NCT05378204NA25 sites📍 Bordeaux📍 Caen📍 Clermont-Ferrand Institut Claudius Regaud · Tests: Main study:, Sub-study: A Study of PARG Inhibitor FORX-428 in Patients With Advanced Solid Tumors. NCT07356453Phase 18 sites📍 Palo Alto📍 San Francisco📍 Grand Rapids FoRx Therapeutics AG · Tests: FORX-428 Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer NCT04090567Phase 21 site📍 Houston M.D. Anderson Cancer Center · Tests: Cediranib, Ceralasertib, Olaparib PARPi or Capecitabine Combined With PD-1 Inhibitors as Adjuvant Therapy in High-risk TNBC NCT06533384Phase 31 site📍 Guangzhou Guangdong Provincial People's Hospital · Tests: As per the germline BRCA1/2 mutation status, the selection of either Fuzuloparib or capecitabine in combination with Ca… An Intervention to Increase Genetic Testing in Families Who May Share a Gene Mutation Related to Cancer Risk and An Intervention to Help Patients and Their Primary Care Providers Stay Up-to-date About Uncertain Genetic Test Results NCT05420064NA8 sites📍 Basking Ridge📍 Middletown📍 Montvale Memorial Sloan Kettering Cancer Center · Tests: Intervention Arm At-risk Relative/ARR Contacts, MyGene Portal, Standard of Care Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer NCT06580314Phase 3695 sites📍 Birmingham📍 Anchorage📍 Anchorage NRG Oncology · Tests: Bevacizumab, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Olaparib Carboplatin Chemotherapy Before Surgery for People With High-Risk Prostate Cancer and an Inherited BRCA1 or BRCA2 Gene Mutation NCT05806515Phase 2133 sites📍 Anchorage📍 Anchorage📍 Anchorage SWOG Cancer Research Network · Tests: Biospecimen Collection, Carboplatin, Chest Radiography, Computed Tomography, Magnetic Resonance Imaging MEASUREMENT OF CIRCULATING MUTATION BURDEN NCT06792721n/a1 site📍 Caen Centre Francois Baclesse · Tests: Mutation Burden cfMB analysis Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation NCT04890613Phase 18 sites📍 Santa Monica📍 Tampa📍 Boston Senhwa Biosciences, Inc. · Tests: CX-5461 A Single-Arm Phase Ⅱ Study of Fluzoparib Maintenance in Platinum-sensitive Advanced Triple-Negative Breast Cance NCT07321015Phase 21 site📍 Tianjin Tianjin Medical University Cancer Institute and Hospital · Tests: Fluzoparib Monotherapy Study of How People Make Decisions About Prostate Cancer Risk NCT07197723n/a1 site📍 New York Memorial Sloan Kettering Cancer Center · Tests: cheek (buccal) swab, Assessments, optional collection of blood Evaluating the Addition of Elacestrant (Oral SERD) to Olaparib (PARP-inhibitor) in Patients With Advanced/Metastatic HR+/HER2- Breast Cancer NCT06201234Phase 236 sites📍 Stuttgart📍 Tübingen📍 Winnenden GBG Forschungs GmbH · Tests: Olaparib + Elacestrant, Olaparib A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer NCT04251052NA574 sites📍 Birmingham📍 Anchorage📍 Anchorage NRG Oncology · Tests: Bilateral Salpingectomy, Bilateral Salpingectomy with Oophorectomy, Biospecimen Collection, Magnetic Resonance Imaging,… TUBectomy With Delayed Oophorectomy in High Risk Women to Assess the Safety of Prevention NCT04294927NA66 sites📍 Chicago📍 Boston📍 Rochester University Medical Center Nijmegen · Tests: Risk-reducing salpingectomy with delayed oophorectomy, Risk-reducing salpingo-oophorectomy The Cancer of the Pancreas Screening-5 CAPS5)Study NCT02000089Phase 39 sites📍 New Haven📍 Baltimore📍 Boston Johns Hopkins University · Tests: Secretin, MRI, Tumor marker gene test with CA19-9 Phase Ib Study of Axatilimab in Combination With Olaparib in BRCA1/2 and PALB2- Associated Metastatic HER2-negative Breast Cancer NCT06488378Phase 12 sites📍 Boston📍 Rochester Dana-Farber Cancer Institute · Tests: Axatilimab, Olaparib Prediction of Germline BRCA 1/2 Genes From Healthy Ovaries NCT05769517n/a1 site📍 Rome Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Tests: Germinal BRCA A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies NCT06395519Phase 1, Phase 214 sites📍 Phoenix📍 New Haven📍 Jacksonville 858 Therapeutics, Inc. · Tests: ETX-19477 Novel Neoadjuvant and Adjuvant Strategy for Germline BRCA 1/2 Mutated Triple Negative Breast Cancer NCT05485766Phase 23 sites📍 Gifu📍 Okayama📍 Tokyo Okayama University · Tests: Pembrolizumab, Paclitaxel, Carboplatin, Olaparib, Definitive Surgery Cognitive Behavioral Therapy for Fear of Cancer Recurrence in Women With BRCA1/2 Gene NCT06817694NA1 site📍 Québec CHU de Quebec-Universite Laval · Tests: Cognitive-behavioral group therapy Responses to Genetic Risk Modifier Testing Among Women With Pathogenic Variants in Breast Cancer Predisposition Genes NCT03396341n/a7 sites📍 Boston📍 Basking Ridge📍 Commack Memorial Sloan Kettering Cancer Center · Tests: Salvia sample, Questionnaires, Buccal swab sample Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer NCT06380751Phase 3306 sites📍 Gilbert📍 Fountain Valley📍 Glendale AstraZeneca · Tests: Saruparib (AZD5305), Camizestrant, Abemaciclib, Ribociclib, Palbociclib Decitabine/Cedazuridine (INQOVI), an Oral DNA Demethylating Agent, in Subjects With BAP1 Cancer Predisposition Syndrome and Subclinical, Early-Stage Mesothelioma NCT05960773Phase 21 site📍 Bethesda National Cancer Institute (NCI) · Tests: Decitabine/cedazuridine Prostate Cancer Genetic Risk Evaluation and Screening Study NCT05129605n/a1 site📍 Boston Massachusetts General Hospital · Tests: Prostate cancer screening APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation NCT04858334Phase 2456 sites📍 Anchorage📍 Anchorage📍 Anchorage National Cancer Institute (NCI) · Tests: Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Olaparib, Placebo Administration Registry of Subjects at Risk of Pancreatic Cancer NCT04095195n/a4 sites📍 Rozzano📍 Peschiera del Garda📍 Milan Associazione Italiana per lo Studio del Pancreas · Tests: MRCP, Endoultrasonography A Bidirectional Cohort Study on Prophylactic Resection Surgery in Populations at Moderate-to-High Risk for Hereditary Ovarian Cancer NCT07532434n/a1 site📍 Beijing Peking University Third Hospital Study to Assess Safety, Tolerability and Activity of DSB2455 in Participants With Advanced Malignancies NCT06458712Phase 121 sites📍 Sacramento📍 New Haven📍 New York Duke Street Bio Ltd · Tests: DSB2455 Prophylactic Irradiation to the Contralateral Breast for BCAs Patients NCT04960839NA8 sites📍 Jiangxi📍 Shanghai📍 Hangzhou Second Affiliated Hospital, Zhejiang University, School of … · Tests: Prophylactic contralateral breast irradiation Serum Biomarkers to Characterize the Effects of Therapy on Ovarian Reserve in Premenopausal Women With Early-stage Breast Cancer or BRCA Mutations NCT00823654n/a8 sites📍 Basking Ridge📍 Middletown📍 Montvale Memorial Sloan Kettering Cancer Center · Tests: Blood draw and questionnaires, Blood draw and questionnaires
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy